These changes were not seen in tumors from patients with replete vitamin D status, supporting a role of phospho-Tau as a downstream effector of Aβ42 signaling in parathyroid cells, specifically in the context of vitamin D deficiency. This evidence concerns the gene MAPT and vitamin D deficiency.